Illuminare Biotechnologies
Illuminare Biotechnologies: NJ-based medical firm reducing nerve damage risk during surgery.
Founded
2016Illuminare Biotechnologies: NJ-based medical firm reducing nerve damage risk during surgery.
Founded in Princeton, New Jersey, Illuminare Biotechnologies is a clinical-stage biotechnology company with a mission to reduce the risk of nerve damage during surgery through advanced intra-operative nerve visualization. The company's core product, Illuminare-1, is a proprietary small molecule designed for immediate and sustained nerve illumination. Currently, Illuminare-1 is undergoing a first-in-human phase 1 clinical trial at Memorial Sloan Kettering Cancer Center, focusing on radical prostatectomy to demonstrate its safety and initial efficacy.
Notable affiliated individuals include leading researchers and clinicians from Memorial Sloan Kettering Cancer Center. Investors and key stakeholders are not publicly disclosed due to the company's stealth mode operations. Illuminare Biotechnologies has achieved significant milestones by advancing Illuminare-1 to clinical trials, indicating strong potential for impactful contributions to surgical procedures and patient outcomes. The company's innovative approach aims to set new standards in surgical safety and precision.
Companies similar to Illuminare Biotechnologies include Alume Biosciences, Inherent Targeting, Illuminant Surgical and Avelas Biosciences.
Illuminare Biotechnologies was founded in 2016.
Illuminare Biotechnologies' headquarters is located in Princeton, NJ, US.
Illuminare Biotechnologies' most recent funding round was for $2.4M (USD) in August 2017.
As of Aug 18, 2017, Illuminare Biotechnologies has disclosed funding of $2.4M (USD). Undisclosed round amounts are excluded.
Illuminare Biotechnologies has 7 employees as of Feb 5, 2024.
Avelas Biosciences
